What is Bluejay Diagnostics Inc's earnings per share (EPS)?

Bluejay Diagnostics Inc (BJDX) reported diluted earnings per share of $-15.25 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bluejay Diagnostics Inc Financials

BJDX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Bluejay Diagnostics Inc (BJDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Bluejay Diagnostics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Bluejay Diagnostics Inc generates $0.88 in operating cash flow (-$6.1M OCF vs -$6.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-8287.2x

Bluejay Diagnostics Inc earns $-8287.2 in operating income for every $1 of interest expense (-$7.0M vs $839). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$6.9M

YoY+3.0%

Bluejay Diagnostics Inc's EBITDA was -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.0% from the prior year.

Net Income

-$6.8M

YoY+11.3%

Bluejay Diagnostics Inc reported -$6.8M in net income in fiscal year 2025. This represents an increase of 11.3% from the prior year.

EPS (Diluted)

$-15.25

Bluejay Diagnostics Inc earned $-15.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 96.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$6.2M

YoY+23.4%

Bluejay Diagnostics Inc generated -$6.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 23.4% from the prior year.

Cash & Debt

$5.2M

YoY+20.1%

5Y CAGR+41.4%

Bluejay Diagnostics Inc held $5.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

604,534

Bluejay Diagnostics Inc had 604,534 shares outstanding in fiscal year 2025. This represents an increase of 336.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-114.6%

YoY+20.1pp

Bluejay Diagnostics Inc's ROE was -114.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.0M

YoY-12.2%

5Y CAGR+42.0%

Bluejay Diagnostics Inc invested $3.0M in research and development in fiscal year 2025. This represents a decrease of 12.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$174K

YoY-43.4%

Bluejay Diagnostics Inc invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 43.4% from the prior year.

BJDX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$249K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	$200K	N/A	N/A
Gross Profit	N/A	N/A	N/A	$49K	N/A	N/A
R&D Expenses	$3.0M-12.2%	$3.5M-39.2%	$5.7M+37.6%	$4.2M+261.7%	$1.1M+117.7%	$527K
SG&A Expenses	$3.9M+5.9%	$3.7M+1201.7%	$283K-37.2%	$451K-74.8%	$1.8M+200.7%	$596K
Operating Income	-$7.0M+3.0%	-$7.2M+30.5%	-$10.3M-10.7%	-$9.3M-188.5%	-$3.2M-170.0%	-$1.2M
Interest Expense	$839-99.9%	$823K	N/A	N/A	$6K-89.3%	$59K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.8M+11.3%	-$7.7M+22.5%	-$10.0M-7.1%	-$9.3M-166.5%	-$3.5M-201.2%	-$1.2M
EPS (Diluted)	$-15.25	$-456.75	$-3631.48	$-9.22	$-0.41	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$786K-11.7%	$890K+13.4%	$785K	N/A	$552K-46.6%	$1.0M-22.6%	$1.3M
SG&A Expenses	N/A	$831K-24.1%	$1.1M-0.8%	$1.1M	N/A	$809K-6.2%	$862K+13325.9%	$6K
Operating Income	N/A	-$1.6M+18.6%	-$2.0M-5.1%	-$1.9M	N/A	-$1.4M+28.2%	-$1.9M+21.9%	-$2.4M
Interest Expense	N/A	$200-9.9%	$222	N/A	N/A	$186K-70.3%	$626K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.6M+18.3%	-$2.0M-4.9%	-$1.9M	N/A	-$1.5M+40.1%	-$2.5M-6.3%	-$2.3M
EPS (Diluted)	N/A	$-1.01+28.4%	$-1.41+58.2%	$-3.37	N/A	$-76.94	$-256.16+35.1%	$-394.76

BJDX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.1M+6.9%	$6.7M+36.7%	$4.9M-64.0%	$13.5M-35.7%	$21.0M+1285.3%	$1.5M
Current Assets	$5.5M+11.5%	$4.9M+52.1%	$3.2M-72.7%	$11.8M-42.9%	$20.7M+1852.4%	$1.1M
Cash & Equivalents	$5.2M+20.1%	$4.3M+94.8%	$2.2M-78.2%	$10.1M-46.9%	$19.0M+1987.7%	$912K
Inventory	N/A	N/A	N/A	N/A	N/A	$85K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M+23.3%	$928K-53.0%	$2.0M-0.3%	$2.0M+210.8%	$637K-88.9%	$5.7M
Current Liabilities	$1.1M+38.1%	$810K-54.3%	$1.8M+8.0%	$1.6M+157.4%	$637K	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.0M+4.3%	$5.7M+97.9%	$2.9M-74.9%	$11.5M-43.4%	$20.4M+584.6%	-$4.2M
Retained Earnings	-$41.5M-19.8%	-$34.7M-28.6%	-$27.0M-58.6%	-$17.0M-120.9%	-$7.7M-82.9%	-$4.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$7.1M+45.6%	$4.9M-23.6%	$6.4M+21.3%	$5.3M-20.7%	$6.7M-20.3%	$8.4M-23.1%	$10.9M+114.0%	$5.1M
Current Assets	$5.5M+63.0%	$3.4M-29.4%	$4.7M+32.9%	$3.6M-27.1%	$4.9M-25.4%	$6.6M-27.2%	$9.0M+161.4%	$3.4M
Cash & Equivalents	$5.2M+67.6%	$3.1M-30.6%	$4.4M+42.6%	$3.1M-27.6%	$4.3M-25.3%	$5.8M-28.6%	$8.1M+202.8%	$2.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M-4.5%	$1.2M+7.6%	$1.1M-21.2%	$1.4M+52.1%	$928K-22.0%	$1.2M-46.4%	$2.2M+29.9%	$1.7M
Current Liabilities	$1.1M-2.6%	$1.1M+10.4%	$1.0M-20.9%	$1.3M+62.5%	$810K-22.8%	$1.0M-49.0%	$2.1M+34.8%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.0M+61.8%	$3.7M-30.2%	$5.3M+36.8%	$3.9M-32.5%	$5.7M-20.0%	$7.2M-17.1%	$8.6M+156.6%	$3.4M
Retained Earnings	-$41.5M-3.6%	-$40.1M-4.2%	-$38.5M-5.4%	-$36.5M-5.4%	-$34.7M-4.3%	-$33.2M-4.7%	-$31.8M-8.5%	-$29.3M

BJDX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.1M+22.6%	-$7.8M+5.9%	-$8.3M-7.4%	-$7.7M-77.3%	-$4.4M-758.4%	-$509K
Capital Expenditures	$174K-43.4%	$307K-56.4%	$704K-41.3%	$1.2M+4908.0%	$24K	N/A
Free Cash Flow	-$6.2M+23.4%	-$8.1M+9.9%	-$9.0M-0.9%	-$8.9M-103.6%	-$4.4M	N/A
Investing Cash Flow	-$174K+43.4%	-$307K+56.4%	-$704K+41.3%	-$1.2M-4908.0%	-$24K	N/A
Financing Cash Flow	$7.1M-30.6%	$10.2M+819.5%	$1.1M+13665.5%	$8K-100.0%	$22.5M+1600.0%	$1.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$1.5M-7.0%	-$1.4M+33.8%	-$2.1M-73.4%	-$1.2M+18.4%	-$1.5M+32.6%	-$2.2M-12.5%	-$1.9M+16.7%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	$1K+395.6%	$227-99.9%	$270K+662.0%	$35K
Free Cash Flow	N/A	N/A	N/A	N/A	-$1.5M+32.6%	-$2.2M+1.4%	-$2.2M+6.4%	-$2.3M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$1K-395.6%	-$227+99.9%	-$270K-662.0%	-$35K
Financing Cash Flow	$3.7M+365736.7%	-$1K-100.0%	$3.4M+343351.6%	-$985+25.7%	-$1K+99.1%	-$148K-102.0%	$7.6M+172.0%	$2.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BJDX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	19.6%	N/A	N/A
Operating Margin	N/A	N/A	N/A	-3741.5%	N/A	N/A
Net Margin	N/A	N/A	N/A	-3733.1%	N/A	N/A
Return on Equity	-114.6%+20.1pp	-134.7%+209.1pp	-343.8%-263.3pp	-80.5%-63.4pp	-17.1%	N/A
Return on Assets	-96.2%+19.7pp	-115.9%+88.5pp	-204.5%-135.7pp	-68.8%-52.2pp	-16.6%+59.7pp	-76.3%
Current Ratio	4.88-1.2	6.05+4.2	1.82-5.4	7.19-25.2	32.43	N/A
Debt-to-Equity	0.19+0.0	0.16-0.5	0.68+0.5	0.17+0.1	0.03+1.4	-1.36
FCF Margin	N/A	N/A	N/A	-3590.1%	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-43.3%-6.3pp	-37.0%+11.2pp	-48.2%	N/A	-20.7%+8.0pp	-28.6%+40.5pp	-69.2%
Return on Assets	N/A	-32.7%-2.1pp	-30.6%+4.8pp	-35.3%	N/A	-17.7%+5.1pp	-22.8%+23.1pp	-45.9%
Current Ratio	4.88+2.0	2.92-1.6	4.56+1.8	2.71-3.3	6.05-0.2	6.26+1.9	4.38+2.1	2.26
Debt-to-Equity	0.19-0.1	0.32+0.1	0.21-0.2	0.37+0.2	0.160.0	0.17-0.1	0.26-0.3	0.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Aethlon Medical AEMD

$3.3M

Catheter Precision VTAK

$2.1M

Nuwellis Inc NUWE

$2.6M

Bone Biologics Corp BBLG

$2.2M

Tivic Health Systems Inc TIVC

$2.9M

Frequently Asked Questions

Is Bluejay Diagnostics Inc profitable?

No, Bluejay Diagnostics Inc (BJDX) reported a net income of -$6.8M in fiscal year 2025.

What is Bluejay Diagnostics Inc's EBITDA?

Bluejay Diagnostics Inc (BJDX) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bluejay Diagnostics Inc's return on equity (ROE)?

Bluejay Diagnostics Inc (BJDX) has a return on equity of -114.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bluejay Diagnostics Inc's free cash flow?

Bluejay Diagnostics Inc (BJDX) generated -$6.2M in free cash flow during fiscal year 2025. This represents a 23.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bluejay Diagnostics Inc's operating cash flow?

Bluejay Diagnostics Inc (BJDX) generated -$6.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bluejay Diagnostics Inc's total assets?

Bluejay Diagnostics Inc (BJDX) had $7.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bluejay Diagnostics Inc's capital expenditures?

Bluejay Diagnostics Inc (BJDX) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bluejay Diagnostics Inc spend on research and development?

Bluejay Diagnostics Inc (BJDX) invested $3.0M in research and development during fiscal year 2025.

How many shares does Bluejay Diagnostics Inc have outstanding?

Bluejay Diagnostics Inc (BJDX) had 604,534 shares outstanding as of fiscal year 2025.

What is Bluejay Diagnostics Inc's current ratio?

Bluejay Diagnostics Inc (BJDX) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.

What is Bluejay Diagnostics Inc's debt-to-equity ratio?

Bluejay Diagnostics Inc (BJDX) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bluejay Diagnostics Inc's return on assets (ROA)?

Bluejay Diagnostics Inc (BJDX) had a return on assets of -96.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bluejay Diagnostics Inc's cash runway?

Based on fiscal year 2025 data, Bluejay Diagnostics Inc (BJDX) had $5.2M in cash against an annual operating cash burn of $6.1M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bluejay Diagnostics Inc's Piotroski F-Score?

Bluejay Diagnostics Inc (BJDX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bluejay Diagnostics Inc's earnings high quality?

Bluejay Diagnostics Inc (BJDX) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bluejay Diagnostics Inc cover its interest payments?

Bluejay Diagnostics Inc (BJDX) has an interest coverage ratio of -8287.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.